News & Updates
Filter by Specialty:
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
14 Nov 2022
byAudrey Abella
In the interim analyses of the phase III CHART trial, a combination regimen of ADT* and the novel second-generation androgen-receptor (AR) inhibitor rezvilutamide trumped the bicalutamide-ADT combination in terms of survival outcomes in individuals with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
14 Nov 2022HKU programme offers free comprehensive genomic profiling tests to NSCLC patients
14 Nov 2022
byChristina Lau
The University of Hong Kong (HKU) has launched a precision oncology programme in partnership with public and private stakeholders to provide free comprehensive genomic profiling tests to 1,800 eligible patients with stage IV non-small-cell lung cancer (NSCLC) in Hong Kong. Initial data from the programme revealed less common mutations amenable to treatment with targeted therapies in a sizeable proportion of patients.